FDA advisory panel votes to lift restrictions on six peptides

After a marathon FDA advisory panel meeting on July 23 and 24, 2026, U.S. health consumers may have wider access to six therapeutic peptides: BPC-157, TB-500, KPV, MOTS-c, epitalon, and Semax.

During the meeting, the Pharmacy Compounding Advisory Committee narrowly voted to add these peptides to the FDA’s 503A Bulks List, a roster of drug substances that specialized licensed pharmacies can use in creating custom mixed medications in a practice called compounding.1

The Pharmacy Compounding Advisory Committee met to evaluate seven restricted peptides for specific uses:2

1. BPC-157 for ulcerative colitis
2. TB-500 for wound-healing
3. KPV for wound-healing and inflammation
4. MOTS-c for obesity and osteoporosis
5. Epitalon for insomnia
6. Semax for cerebral ischemia, migraine, and trigeminal neuralgia
7. Emideltide (DSIP) for opioid withdrawal, chronic insomnia, and narcolepsy

The committee voted in favor of lifting restrictions on only the first six. They rejected emideltide because of weak evidence in its support.

Previously, the peptides in question were severely restricted because of safety concerns, and pharmaceutical-grade forms were available only via limited channels. A patient could either:

• Qualify for “compassionate use,” in which they demonstrated a health-based need for an experimental drug;3 or
• Go through a licensed peptide clinic operating within a regulatory gray area, in which the FDA did not universally enforce restrictions.

The committee did not vote unanimously. Concerning BPC-157, for example, six committee members voted against its inclusion on the Bulks List, and one abstained. Most of the “yes” votes came from members with vested interests in the peptide industry.14

Generally, the “no” voters reasoned that the peptides under review lacked sufficient safety research. But ironically, among committee members who voted “yes,” safety was one of the most commonly cited reasons. They argued that to retain restrictions would push the peptides further onto the gray market, where the absence of regulatory oversight could proliferate the use of research-only drugs with high proportions of contaminants. In their view, placing these peptides on the Bulks List serves the greater good better than the alternative.

The gray market is how many users have circumvented the restrictions and official prescription channels to date. There, peptides labeled “for research purposes only” may contain a high proportion of contaminants that can cause life-threatening reactions, including septic shock and anaphylaxis.4 5

The committee’s vote does not equal FDA approval but is instead a formal recommendation that the administration should loosen restrictions on availability. Officially, even with the committee’s recommendation, the peptides have not moved out of the regulatory gray area, but will do so if the FDA accepts the committee’s recommendation.

In this case, heeding the recommendation would allow ordinary doctors to prescribe any of the six peptides to indicated patients without meeting “compassionate use” requirements.

"Placement on the 503A Bulks List would satisfy one statutory condition allowing qualifying physicians and pharmacists to compound products from these bulk substances; all other applicable compounding requirements would still apply," explained Mark Matus, MD, family medicine resident physician. "It would not establish an approved indication, standardized dose, demonstrated efficacy, or an FDA-reviewed safety profile."

For FDA approval, the peptides would need to undergo large and rigorous randomized controlled trials to validate their efficacy and safety. On average, the approval process for new drugs takes 12 years.6

The peptide clinics we’ve consulted generally agree that moving popular-but-restricted peptides to the Bulks List would do more to serve the public health interest than harm it.

“If the FDA adopts the recommendations, it could create a more clearly defined pathway for appropriately licensed and credentialed pharmacies to compound certain peptides pursuant to patient-specific prescriptions," said Susan Braddock, CEO of Bridgeside Telehealth, a platform offering pharmaceutical-grade peptide therapies. "Patients could have safer access to peptides through licensed compounding pharmacies with a valid prescription ... . No more wondering if the peptide is pure, safe, and actually what was ordered. It's clearly a first step in the right direction.”

Braddock’s opinion is grounded in regulatory process since being on the Bulks List means a drug must have traceable ingredients and undergo testing for contamination. When we spoke with doctors, their opinions often acknowledged this reality but also a lingering concern over safety.

"Overall, I would think that this represents a modest improvement in safety, assuming nothing changes since this recent FDA recommendation," radiologist Omar Abbas, MD, told us. "Right now these peptides are largely bought online with no oversight at all, and testing has found purity as low as 5 percent along with contamination from heavy metals like arsenic and lead. ... At the same time, however, this recommendation does not automatically equate to a safety or efficacy endorsement. 503A compounding still does not require FDA premarket review or standardized testing, and therefore much of the underlying uncertainty simply shifts to a different part of the supply chain rather than being resolved."

Indeed, the question of safety, as well as efficacy, is at the forefront of why many health officials oppose lifting restrictions.

In documents released leading up to the panel meeting, the FDA itself expressed that the evaluation criteria “weigh against” broadening the compounding of experimental drugs like BPC-157, citing limited evidence for unapproved peptides and the availability of currently approved medications with actual research support behind them.7

Medical practitioners are quick to emphasize what is still unknown.

"The current evidence behind these peptides is mixed," Dr. Abbas explained. "BPC-157 has decades of animal data supporting it, but the human evidence is limited to fewer than 30 subjects across a handful of uncontrolled pilot studies, and there has still never been a completed Phase II trial. Epitalon and Semax rely mostly on older trials conducted in Russia that would not meet current regulatory standards in the U.S."

"For KPV, TB-500, and MOTS-c, FDA reported finding no human exposure data," noted Dr. Matus.

There are also concerns over the implications of the committee’s decision. Apart from the inherent risks that unproven peptide therapies may pose,8 it may set a potentially dangerous precedent in which a drug’s availability hinges on health market trends instead of clinical research, and could send the wrong message to the public.

"The principal public-health concern is false reassurance," Dr. Matus told us. "Consumers may incorrectly interpret an advisory committee recommendation as proof that these peptides are FDA-approved, proven effective, or established as safe. None of those conclusions follows from the committee’s vote. At this stage, I would view the development as uncertain rather than clearly positive or negative."

The committee’s vote reflects an ongoing shift in a larger public health discussion tied to Health Secretary Kennedy's contrarian position on mainstream health consensus.9 He has said that he’s a “big fan of peptides” and uses them himself.10

It was under Secretary Kennedy’s watch that the FDA announced its plan to convene the advisory committee for its first peptide review meeting in July 2026.11 It was Mr. Kennedy, too, who appointed eight new members to the Pharmacy Compounding Advisory Committee in the weeks leading up to the panel meeting.12

With these new members, the committee heavily consisted of clinicians who prescribe peptides and other people with ties to the peptide industry. The updated member roster stood in contrast to past panels that were largely composed of independent academics and researchers.13

During the July 23–24 panel meetings, the new appointees generally voted to lift restrictions, whereas others tended to vote against.

Figures in the growing fitness and biohacking influencer community have responded to the vote with enthusiasm, many touting that it represents a win for medical freedom.

Their stance stands in conflict with that of numerous medical experts concerned about both the direct consequences of peptide derestriction and the downstream effects thereof.

Now it’s up to the FDA to decide whether it will follow the committee’s recommendation to lift restrictions on BPC-157, TB-500, KPV, MOTS-c, epitalon, and Semax.

The FDA doesn’t always heed the committee, but usually does.

The committee is scheduled to meet once more in February 2027, again to discuss lifting restrictions on peptides: LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF.

In the meantime, peptide proponents have gained significant political momentum. Yet scientific questions as to peptide efficacy and safety remain.

“I will be watching this closely,” said Dr. Abbas. “Drugs that have historically been approved without randomized controlled trial data tend to accumulate more safety warnings and label changes over time. It is too early to tell whether that pattern will hold for compounded peptides, and tracking the data as it emerges will be critical for clinicians and patients alike.”

Dr. Matus recommended a cautious approach. "Patients should not interpret these votes as a reason to replace established therapies with compounded peptides," he said. "Clinicians should clearly distinguish biological plausibility, animal research, and anecdotal reports from demonstrated benefit in well-conducted human trials. The committee’s recommendations are advisory, and no final FDA action adding these substances to the 503A Bulks List has yet occurred."

The views expressed here in quoted statements are the individuals' personal opinions and do not constitute medical advice, nor do they represent the views or positions of any current or past employer or affiliated institution.